vs
Enact Holdings, Inc.（ACT）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是Orthofix Medical Inc.的1.4倍（$312.7M vs $219.9M），Enact Holdings, Inc.同比增速更快（3.6% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 3.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ACT vs OFIX — 直观对比
营收规模更大
ACT
是对方的1.4倍
$219.9M
营收增速更快
ACT
高出1.6%
2.0%
两年增速更快
OFIX
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 71.3% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 3.6% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $1.23 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTOFIX
| Q4 25 | $312.7M | $219.9M | ||
| Q3 25 | $311.5M | $205.6M | ||
| Q2 25 | $304.9M | $203.1M | ||
| Q1 25 | $306.8M | $193.6M | ||
| Q4 24 | $301.8M | $215.7M | ||
| Q3 24 | $309.6M | $196.6M | ||
| Q2 24 | $298.8M | $198.6M | ||
| Q1 24 | $291.6M | $188.6M |
净利润ACTOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | — | $-22.8M | ||
| Q2 25 | — | $-14.1M | ||
| Q1 25 | — | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | — | $-27.4M | ||
| Q2 24 | — | $-33.4M | ||
| Q1 24 | — | $-36.0M |
毛利率ACTOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率ACTOFIX
| Q4 25 | 71.3% | 0.2% | ||
| Q3 25 | 67.4% | -8.3% | ||
| Q2 25 | 70.4% | -7.9% | ||
| Q1 25 | 68.9% | -25.2% | ||
| Q4 24 | 68.9% | -5.3% | ||
| Q3 24 | 74.1% | -9.6% | ||
| Q2 24 | 78.6% | -12.5% | ||
| Q1 24 | 70.6% | -15.6% |
净利率ACTOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | — | -11.1% | ||
| Q2 25 | — | -6.9% | ||
| Q1 25 | — | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | — | -13.9% | ||
| Q2 24 | — | -16.8% | ||
| Q1 24 | — | -19.1% |
每股收益（稀释后）ACTOFIX
| Q4 25 | $1.23 | $-0.05 | ||
| Q3 25 | $1.10 | $-0.57 | ||
| Q2 25 | $1.11 | $-0.36 | ||
| Q1 25 | $1.08 | $-1.35 | ||
| Q4 24 | $1.05 | $-0.76 | ||
| Q3 24 | $1.15 | $-0.71 | ||
| Q2 24 | $1.16 | $-0.88 | ||
| Q1 24 | $1.01 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $82.0M |
| 总债务越低越好 | $744.5M | — |
| 股东权益账面价值 | $5.4B | $450.0M |
| 总资产 | $6.9B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTOFIX
| Q4 25 | $582.5M | $82.0M | ||
| Q3 25 | $545.6M | $62.9M | ||
| Q2 25 | $616.0M | $65.6M | ||
| Q1 25 | $639.0M | $58.0M | ||
| Q4 24 | $602.8M | $83.2M | ||
| Q3 24 | $674.9M | $30.1M | ||
| Q2 24 | $711.3M | $26.4M | ||
| Q1 24 | $624.3M | $27.0M |
总债务ACTOFIX
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | $157.2M | ||
| Q2 25 | $743.8M | $157.0M | ||
| Q1 25 | $743.4M | $156.9M | ||
| Q4 24 | $743.0M | $157.0M | ||
| Q3 24 | $742.7M | $118.5M | ||
| Q2 24 | $742.4M | $118.0M | ||
| Q1 24 | $746.1M | $118.2M |
股东权益ACTOFIX
| Q4 25 | $5.4B | $450.0M | ||
| Q3 25 | $5.3B | $442.5M | ||
| Q2 25 | $5.2B | $458.3M | ||
| Q1 25 | $5.1B | $458.3M | ||
| Q4 24 | $5.0B | $503.1M | ||
| Q3 24 | $5.0B | $525.9M | ||
| Q2 24 | $4.8B | $546.0M | ||
| Q1 24 | $4.7B | $570.3M |
总资产ACTOFIX
| Q4 25 | $6.9B | $850.6M | ||
| Q3 25 | $6.9B | $832.6M | ||
| Q2 25 | $6.8B | $837.2M | ||
| Q1 25 | $6.7B | $823.1M | ||
| Q4 24 | $6.5B | $893.3M | ||
| Q3 24 | $6.6B | $867.9M | ||
| Q2 24 | $6.3B | $882.0M | ||
| Q1 24 | $6.3B | $906.0M |
负债/权益比ACTOFIX
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | 0.36× | ||
| Q2 25 | 0.14× | 0.34× | ||
| Q1 25 | 0.15× | 0.34× | ||
| Q4 24 | 0.15× | 0.31× | ||
| Q3 24 | 0.15× | 0.23× | ||
| Q2 24 | 0.15× | 0.22× | ||
| Q1 24 | 0.16× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ACTOFIX
| Q4 25 | $724.5M | $27.7M | ||
| Q3 25 | $192.0M | $12.4M | ||
| Q2 25 | $119.5M | $11.6M | ||
| Q1 25 | $226.7M | $-18.4M | ||
| Q4 24 | $686.3M | $23.7M | ||
| Q3 24 | $188.1M | $11.7M | ||
| Q2 24 | $144.7M | $9.0M | ||
| Q1 24 | $187.3M | $-18.6M |
自由现金流ACTOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率ACTOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度ACTOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
